Blood Journals Portfolio
@BloodPortfolio
Followers
54K
Following
434
Media
6K
Statuses
9K
Portfolio of ASH journals including Blood, Blood Advances, Blood Global Hematology, Blood ICT, Blood Neoplasia, Blood RCI, and Blood VTH.
Joined August 2015
New Blood Advances issue out now featuring: A simple and efficient method for the robust expansion of human ILC2s to prevent acute GVHD https://t.co/4zQ8zaOop7
0
3
16
CART in MCL: risk and reward? https://t.co/vrKMDFPji8
#immunobiologyandimmunotherapy #lymphoidneoplasia #InsideBloodAdvances #IBAs
ashpublications.org
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has revolutionized the management of several lymphoma subtypes, including mantle cell lymphoma (MC
0
3
17
Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma https://t.co/5uhHyDOdbA
#BloodWork #lymphoidneoplasia
0
5
15
Model 3 and Model Y battery packs retain 85% of their capacity on average after 200K miles of driving We also offer an 8 years or 120,000 miles battery warranty, whichever comes first
0
98
1K
Young HID is associated with less relapse, whereas older MSD is associated with less treatment-related mortality. https://t.co/PEa1kbsNWy
#clinicaltrialsandobservations #myeloidneoplasia #transplantation
0
2
8
Dr. Philippe Armand chats with Drs. Erin Parry, Sarah Rutherford, and Carla Casulo in this week's Review Series on the Blood Podcast. 🔊Review Series on Follicular Lymphoma 🎧 https://t.co/1DxcvosN3e
@drsarahruth
0
2
8
Innate lymphocytes were relatively more frequent in the marrow than the blood; marrow T cell phenotype correlated with leukemia relapse. https://t.co/tbm5QHK0A3
#immunobiologyandimmunotherapy #transplantation
1
6
22
New Blood issue out now featuring: Epidemiology, clinical features, and molecular basis of TTMV::RARA-driven acute promyelocytic leukemia https://t.co/wRUt8mA2cZ
1
2
13
Olutasidenib: an Achilles’ heel for IDH1-mutated MDS? https://t.co/SxW1LuHQDo
#clinicaltrialsandobservations #myeloidneoplasia #InsideBloodAdvances #IBAs
ashpublications.org
In this issue of Blood Advances, Cortes et al report encouraging outcomes in patients with isocitrate dehydrogenase 1 (IDH1)–mutated relapsed/refractory (R
1
1
17
Embarrassment of riches: which donor for allo-transplant? https://t.co/Nc9AuiyalA
#clinicaltrialsandobservations #myeloidneoplasia #transplantation #InsideBloodAdvances #IBAs
ashpublications.org
For patients with acute myeloid leukemia (AML) in their first complete remission, the prospect of an allogeneic transplantation comes with the task of graf
0
5
20
Post-HCT gilteritinib outweighs conditioning in NPM1m FLT3-ITD AML https://t.co/jSoLUxCqcU
#clinicaltrialsandobservations #myeloidneoplasia #InsideBloodAdvances #IBAs
ashpublications.org
In this issue of Blood Advances, Levis et al1 report a post hoc analysis of data from the Blood and Marrow Transplant Clinical Trials Network 1506 (MORPHO)
0
5
31
Assessment of classical hematologists and classical hematology fellowship programs at NCI-designated cancer centers https://t.co/j4f1hJm3jg
#healthservicesandoutcomes
0
2
14
Updating clinical guidelines with limited evidence: case study of ASH/ISTH pediatric VTE treatment guidelines https://t.co/16fEhF8kYn
#healthservicesandoutcomes #thrombosisandhemostasis
ashpublications.org
TO THE EDITOR:
0
3
3
MADDlessness may cause von Willebrand disease type 1 https://t.co/hcOWvQTnVm
#thrombosisandhemostasis
0
1
7
Leukemic fusion: partners and mutations shape NUP98r leukemia https://t.co/lrkJUKAFqy
#myeloidneoplasia
ashpublications.org
In this issue of Blood, Umeda et al1 show that the diverse phenotypes of NUP98-rearranged (NUP98r) leukemias are shaped by specific fusion partners, which
0
3
16
Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up https://t.co/n3we0dvLU4
#clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia
0
5
18
Patient-specific enhancers in genetically uniform leukemias https://t.co/AH9vDxBDmj
#lymphoidneoplasia
0
5
25
🚨Exciting Update: The Blood Podcast has a new format featuring interview style discussions of recent published articles! Listen to Breakthroughs in Multiple Myeloma Treatment and Von Willebrand Disease Mechanisms. 🎧 https://t.co/inZgPmiExB
0
2
8
Time for iMDSCs: off-the-shelf MDSCs to control GVHD https://t.co/skvvLPNiyd
#immunobiologyandimmunotherapy
ashpublications.org
In this issue of Blood, Ma et al1 report a novel approach to generate off-the-shelf, myeloid-derived suppressor cells (MDSCs) from human-induced pluripoten
0
1
2
iMDSCs expressed phosphoglycerate dehydrogenase, required to overcome GVHD-related, inflammasome-induced loss of suppressor function. https://t.co/hhi5vhzzvJ
#hematopoiesisandstemcells #immunobiologyandimmunotherapy #transplantation
0
1
9
📉Democrats losing shutdown fight Democrats are losing the media and the voters as their shutdown political game drags on, and Senator Sheldon Whitehouse admits that they are starving people because “its’ the only lever they have.”
7
162
533
New Blood Advances issue is out now featuring: Ethical considerations for hematologic precursor conditions https://t.co/3Ns65mjbsZ
0
2
11
Differential enhancer activity contributes to oncogene overexpression and transcriptional diversity in primary KMT2A::AFF1 leukemia samples. https://t.co/C4mYYBTvCV
#lymphoidneoplasia
0
5
13